

## Catalog # 10-4126 RO-3306

CAS# 872573-93-8 5-(6-Quinolinylmethylene)-2-[(2-thienylmethyl)amino]-4(5H)-thiazolone Lot # JKM1166



RO-3306 is a selective inhibitor of CDK1 ( $IC_{50} = 35$  nM versus CDK2  $IC_{50} = 340$  nM).<sup>1,2</sup> It induces G2/M phase cell cycle arrest and apoptosis. Inhibition of CDK1 with RO-3306 has been shown to have synergistic effects with PARP inhibitors in treating various breast cancers.<sup>3,4</sup> It has also been demonstrated to overcome apoptotic resistance in BRAF<sup>V600E</sup> human colorectal cancer cells.<sup>5</sup>

- 1) Vassilev *et al.* (2006), Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1; Proc.Nat.Acad.Sci.USA **103** 10660
- Krasinska et al. (2008), Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle; Cell Cycle 7 1702
- 3) Pierce et al. (2013), Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triplenegative breast cancer cell lines; Cancer Biol.Ther. **14** 537
- 4) Xia et al. (2014), The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition; Int.J.Oncol. 44 735
- 5) Zhang et al. (2018), Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer, Mol.Cancer Res. **16** 378

## PHYSICAL DATA

Molecular Weight:	351.45
Molecular Formula:	C18H13N3OS2
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (15 mg/ml)
Physical Description:	Off-white/very pale yellow solid
Storage and Stability:	Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in
	DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.